GlassScriptPhysician profile
Meaghan Primm
NPI 1992259451
$2,250.15
in general payments reported to CMS, 2019-2025
21 companies · $249 in 2025
The $249 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.89 · 2020: $97.24 · 2021: $306 · 2022: $748 · 2023: $531 · 2024: $296 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,046 · Long Term Medical Supply Or Device Loan: $29.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,046.02 |
| Long Term Medical Supply Or Device Loan | $29.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $575.22 | 2021-2025 | |
| Glaxosmithkline, LLC. | $357.12 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Phathom Pharmaceuticals, INC. | $170.92 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $164.13 | 2020-2023 | Jardiance, Mounjaro |
| Abbott Laboratories | $138.98 | 2022-2025 | Freestyle Insulinx |
| Biohaven Pharmaceuticals, INC. | $125.00 | 2021 | |
| Pfizer INC. | $106.85 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.67 | 2020-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $88.79 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $77.22 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Biohaven Pharmaceutical Holding Company LTD. | $69.48 | 2022 | |
| Novo Nordisk INC | $67.66 | 2019-2024 | Ozempic, Rybelsus |
| Advanced Oxygen Therapy INC. | $53.95 | 2023 | Topical Oxygen Chamber For Extremities |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.68 | 2023 | Trulance, Xifaxan |
| Exact Sciences Corporation | $27.00 | 2023 | Cologuard Collection Kit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $21.24 | 2025 | Gemtesa |
| Amgen INC. | $19.68 | 2022 | |
| Amarin Pharma, INC. | $17.21 | 2022 | |
| Organon LLC | $16.02 | 2023 | Nexplanon |
| Smith+Nephew, INC. | $15.39 | 2022 | |
| Astellas Pharma US INC | $14.94 | 2023 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meaghan Primm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.